drugset / Trial / NCT00986401

Safety and Tolerability of Trospium Chloride and Metformin Hydrochloride in Healthy Subjects

NCT00986401

Phase 1 Completed 44 enrolled Allergan
RandomizedCrossoverOpen-label

Summary

The purpose of this study is to investigate the safety and tolerability of trospium chloride (Sanctura XR™) and metformin hydrochloride (Glucophage) when co-administered.

Timeline

Start
2009-10
Primary completion
2009-11
Completion
2009-11

Drugs

EvaluationDrugModalityDoseRoute
Subject Metformin Small molecule 500 mg Oral
Subject Trospium Small molecule 60 mg Oral

Indications

No indication recorded.